Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evoq RemediesBOM:543500 +4.57%60 Piotroski F-Score is 4 as of Aug. 05, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates BOM:543500 with a GF Score™ of 60/100 and a GF Value™ of ₹12.94 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 113 Medical Distribution companies, Evoq Remedies ranks worse than 62.83% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Evoq Remedies has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Evoq Remedies's Piotroski F-Score or its related term are showing as below:
BOM:543500'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 7
Current: 4
During the past 8 years, the highest Piotroski F-Score of Evoq Remedies was 7. The lowest was 4. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Evoq Remedies Piotroski F-Score Related Terms
Evoq Remedies Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Evoq Remedies's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543500 vs MCK, COR, CAH: Piotroski F-Score Comparison
For the Medical Distribution subindustry, Evoq Remedies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoq Remedies Piotroski F-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Evoq Remedies's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Evoq Remedies's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Evoq Remedies's current Net Income (TTM) was -2.4.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Evoq Remedies's return on assets of this year was -0.0047971. Evoq Remedies's return on assets of last year was 0.00239277.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Evoq Remedies's current ratio of this year was 6.77261012. Evoq Remedies's current ratio of last year was 9.09604633.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Evoq Remedies's number of shares in issue this year was 23.99. Evoq Remedies's number of shares in issue last year was 24.9.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Evoq Remedies's gross margin of this year was 0.00124673. Evoq Remedies's gross margin of last year was -0.11268468.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Evoq Remedies's asset turnover of this year was 0.51004011. Evoq Remedies's asset turnover of last year was 0.31894685.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
0
+
1
+
0
+
1
+
1
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Evoq Remedies has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Evoq Remedies (BOM:543500) has a Piotroski F-Score of 4 as of Aug. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Evoq Remedies and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Evoq Remedies' Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Evoq Remedies ranks #71 out of 113 companies in the Medical Distribution industry, placing it in the top 62.8%.
Is Evoq Remedies' Piotroski F-Score too high?
Evoq Remedies' current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Evoq Remedies' value of 4 is 20% below this industry median. Based on the distribution chart, Evoq Remedies ranks #71 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Evoq Remedies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evoq Remedies' Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Evoq Remedies ranks #71 out of 113 companies for Piotroski F-Score. This places Evoq Remedies in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Evoq Remedies' value of 4 is 20% below this benchmark. Historically, Evoq Remedies' own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Evoq Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evoq Remedies's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Evoq Remedies and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evoq Remedies's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evoq Remedies stock overvalued right now?
Based on GuruFocus' analysis, Evoq Remedies (BOM:543500) is currently considered Possible Value Trap. The stock's GF Value™ is ₹12.94, compared to a current price of ₹1.83 — trading 85.9% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Distribution industry median of 5.00. Evoq Remedies' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Evoq Remedies (BOM:543500), the current Piotroski F-Score is 4 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evoq Remedies (BOM:543500) Overvalued in 2026?
Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued.
The current stock price of ₹1.83 is trading 85.9% below its estimated GF Value™ of ₹12.94.
GuruFocus considers Evoq Remedies to be Possible Value Trap.
Key valuation signals for BOM:543500:
Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
GF Value™: ₹12.94 vs. price of ₹1.83 (85.9% below fair value)
Industry Position: 20% below the Medical Distribution median (#71 of 113)
No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
60GF Score
Get the complete analysis for BOM:543500
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543500 has been successfully added to your 
